D J Handelsman, B Yeap1, L Flicker1, S Martin2, G A Wittert2, Lam P Ly. 1. AndrologyANZAC Research Institute, University of Sydney, Sydney, New South Wales 2139, AustraliaSchool of Medicine and PharmacologyUniversity of Western Australia, Perth, Western Australia, AustraliaDepartment of Endocrinology and DiabetesFiona Stanley Hospital, Perth, Western Australia, AustraliaWestern Australian Centre for Health and AgingCentre for Medical Research, University of Western Australia, Perth, Western Australia, AustraliaDiscipline of MedicineUniversity of Adelaide, Adelaide, South Australia, Australia AndrologyANZAC Research Institute, University of Sydney, Sydney, New South Wales 2139, AustraliaSchool of Medicine and PharmacologyUniversity of Western Australia, Perth, Western Australia, AustraliaDepartment of Endocrinology and DiabetesFiona Stanley Hospital, Perth, Western Australia, AustraliaWestern Australian Centre for Health and AgingCentre for Medical Research, University of Western Australia, Perth, Western Australia, AustraliaDiscipline of MedicineUniversity of Adelaide, Adelaide, South Australia, Australia. 2. AndrologyANZAC Research Institute, University of Sydney, Sydney, New South Wales 2139, AustraliaSchool of Medicine and PharmacologyUniversity of Western Australia, Perth, Western Australia, AustraliaDepartment of Endocrinology and DiabetesFiona Stanley Hospital, Perth, Western Australia, AustraliaWestern Australian Centre for Health and AgingCentre for Medical Research, University of Western Australia, Perth, Western Australia, AustraliaDiscipline of MedicineUniversity of Adelaide, Adelaide, South Australia, Australia.
Abstract
AIM: The age-specific population profiles in men of circulating testosterone and its two bioactive metabolites dihydrotestosterone (DHT) and estradiol (E2) across the adult lifespan and its determinants are not well described. OBJECTIVE: Our objective was to deduce smoothed age-specific centiles of circulating testosterone, DHT, and E2 in men using pooled data from population-based studies in three Australian cities from liquid chromatography-mass spectrometry steroid measurements in a single laboratory. DESIGN, SETTING, AND PARTICIPANTS: We pooled data of 10 904 serum samples (serum testosterone, DHT, E2, age, height, and weight) from observational population-based studies in three major cities across Australia. MAIN OUTCOME MEASURES: Age-specific smoothed centiles for serum testosterone, DHT, and E2 in men aged 35-100 years were deduced by large sample data analysis methods. RESULTS: We found that serum testosterone, DHT, and E2 decline gradually from ages 35 onwards with a more marked decline after 80 years of age. Higher weight, BMI, and body surface area as well as shorter stature are associated with reduced serum testosterone, DHT, and E2. CONCLUSIONS: Among Australian men, there is a gradual progressive population-wide decline in androgen status during male aging until the age of 80 years after which there is a more marked decline. Obesity and short stature are associated with reduced androgen status. Research into the age-related decline in androgen status should focus on the progressive accumulation of age-related comorbidities to better inform optimal clinical trial design.
AIM: The age-specific population profiles in men of circulating testosterone and its two bioactive metabolites dihydrotestosterone (DHT) and estradiol (E2) across the adult lifespan and its determinants are not well described. OBJECTIVE: Our objective was to deduce smoothed age-specific centiles of circulating testosterone, DHT, and E2 in men using pooled data from population-based studies in three Australian cities from liquid chromatography-mass spectrometry steroid measurements in a single laboratory. DESIGN, SETTING, AND PARTICIPANTS: We pooled data of 10 904 serum samples (serum testosterone, DHT, E2, age, height, and weight) from observational population-based studies in three major cities across Australia. MAIN OUTCOME MEASURES: Age-specific smoothed centiles for serum testosterone, DHT, and E2 in men aged 35-100 years were deduced by large sample data analysis methods. RESULTS: We found that serum testosterone, DHT, and E2 decline gradually from ages 35 onwards with a more marked decline after 80 years of age. Higher weight, BMI, and body surface area as well as shorter stature are associated with reduced serum testosterone, DHT, and E2. CONCLUSIONS: Among Australian men, there is a gradual progressive population-wide decline in androgen status during male aging until the age of 80 years after which there is a more marked decline. Obesity and short stature are associated with reduced androgen status. Research into the age-related decline in androgen status should focus on the progressive accumulation of age-related comorbidities to better inform optimal clinical trial design.
Authors: Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh Journal: Endocr Rev Date: 2017-06-01 Impact factor: 19.871
Authors: Yi X Chan; Helman Alfonso; S A Paul Chubb; David J Handelsman; P Gerry Fegan; Graeme J Hankey; Jonathan Golledge; Leon Flicker; Bu B Yeap Journal: Horm Cancer Date: 2017-02-23 Impact factor: 3.869
Authors: Rebecca E Graff; Thomas U Ahearn; Andreas Pettersson; Ericka M Ebot; Travis Gerke; Kathryn L Penney; Kathryn M Wilson; Sarah C Markt; Claire H Pernar; Amparo G Gonzalez-Feliciano; Mingyang Song; Rosina T Lis; Daniel R Schmidt; Matthew G Vander Heiden; Michelangelo Fiorentino; Edward L Giovannucci; Massimo Loda; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-11-22 Impact factor: 4.254
Authors: Joel S Finkelstein; Hang Lee; Sherri-Ann M Burnett-Bowie; Karin Darakananda; Emily C Gentile; David W Goldstein; Sarah H Prizand; Laura M Krivicich; Alexander P Taylor; Kendra E Wulczyn; Benjamin Z Leder; Elaine W Yu Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958
Authors: Eliza C B Jaeger; L Erin Miller; Emily C Goins; Chloe E Super; Christina U Chyr; John W Lower; Lauren S Honican; Daryl E Morrison; Rajan A Ramdev; Mark D Spritzer Journal: Psychoneuroendocrinology Date: 2019-12-19 Impact factor: 4.905